Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

References

• Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Pamo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581–1590.
   PubMed Web of Science ®Google Scholar
• Kaysen G. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73–77.
   PubMed Web of Science ®Google Scholar
• Rosenblat M, Volkova N, Ward I, Aviram M. Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation. Atherosclerosis. 2011;219:49–56.
   PubMed Web of Science ®Google Scholar
• Gugliucci A, Kotani K, Kimura S. Paraoxonase 1 in chronic kidney failure. J Lipids. 2012;2012:726048.
   PubMedGoogle Scholar
• Mackness M, Mackness B, Durringrton PN. Paraoxonase and coronary heart disease. Atherosclerosis Suppl. 2002;3:49–55.
   PubMed Web of Science ®Google Scholar
• Precourt LP, Amre D, Deni MC, Lavoie JC, Delvib E, Seldman E. The three-gene paraoxonase family: Physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20–36.
   PubMed Web of Science ®Google Scholar
• Schiavon R, Battaglia P, De Fanti E, et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: Comparison with the PON1 allele polymorphism. Clin Chim Acta. 2002;324:39–44.
   PubMed Web of Science ®Google Scholar
• Kontush A Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Ather Thromb Vasc Biol. 2003;23:1881–1888.
   PubMed Web of Science ®Google Scholar
• Lewis D, Haynes R, Landray M. Lipids in chronic kidney disease. J Ren Care. 2010;36:27–33.
   PubMedGoogle Scholar
• Vaziri N, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6:287–296.
   PubMed Web of Science ®Google Scholar
• Samouilidou E, Karpouza A, Grapsa E, Tzanatou-Exarchou H. Serum oxidized LDL is inversely associated with HDL2-cholesterol subclass in renal failure patients on hemodialysis. Nephron Clin Pract. 2010;115:c289–c294.
   Google Scholar
• Kennedy D, Tang W, Fan Y, Wu Y, Mann S, Pepoy BS. Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc. 2013;2:e000104. doi:1161/JAHA.112.000104.
   Web of Science ®Google Scholar
• Johnson-Davis K, Fernalius C, Eliason N, Wilson A, Beddhu S, Roberts W. Blood enzymes and oxidative stress in chronic kidney disease: A cross sectional study. Ann Clin Lab Sci. 2011;41:331–339.
   PubMed Web of Science ®Google Scholar
• Kotur-Stevuljevic J, Peco-Antic A, Spasic S, et al. Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease. Pediatr Nephr. 2013;28:295–303.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Suehiro T, Itahara T, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol. 2007;67:358–365.
   PubMed Web of Science ®Google Scholar
• Harangi M, Seres I, Harangi J, Paragh G. Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment. Cardiovasc Drugs Ther. 2009;23:501–510.
   PubMed Web of Science ®Google Scholar
• Miyamoto-Sasaki M, Yasuda T, Mongushi T, et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Ather Thromb. 2013;20:708–716.
   PubMed Web of Science ®Google Scholar
• Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y. A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. J Lipid Res. 2008;49:1130–1136.
   PubMed Web of Science ®Google Scholar
• Puchades MJ, Saez G, Munez MC, et al. Study of oxidative stress in patients with advanced renal disease and undergoing either hemodialysis or peritoneal dialysis. Clin Nephrol. 2013;80:177–186.
   PubMed Web of Science ®Google Scholar
• Kimak E, Ksiazek A, Solski J. Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure. Clin Chem Lab Med. 2006;44:64–69.
   PubMed Web of Science ®Google Scholar
• Marsillach J, Martinez-Vea A, Mareas L, Mackness B, Mackness M, Ferré N. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin Exp Pharmacol Physiol. 2007;34:347–349.
   PubMed Web of Science ®Google Scholar
• Suehiro T, Ikeda Y, Shiinoki T, et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb. 2002;9:133–138.
   PubMedGoogle Scholar
• Gugliucci A, Kinusa E, Ogata H, Caccavello A, Kimura S. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL. Clin Chim Acta. 2014;430:9–14.
   PubMed Web of Science ®Google Scholar
• Patra SK, Singh K, Singh R. Paraoxonase 1: a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus. Diabetes Metab Syndr. 2014;7:108–111.
   Google Scholar
• Alabakova S, Todorova S, Labudovic D, Tosheska K. LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem. 2002;35:211–216.
   PubMed Web of Science ®Google Scholar
• Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481–488.
   PubMed Web of Science ®Google Scholar
• Ribeiro S, do Sameiro Faria M, Mascarenhas-Melo F, et al. Main determinants of PON1 activity in hemodialysis patients. Am J Nephrol. 2012;36:317–323.
   PubMed Web of Science ®Google Scholar